Of several radiolabeled ligands reported in the literature, the radiopharmaceutical 177Lu-PSMA-617 has been one of the most extensively studied PSMA radioligands for both prostate cancer imaging and therapy. This evidence concerns the gene FOLH1 and prostate cancer.